Cargando…
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
BACKGROUND: The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted therapies. The oncogenic signaling pathways...
Autores principales: | She, Qing-Bai, Gruvberger-Saal, Sofia K., Maurer, Matthew, Chen, Yilun, Jumppanen, Mervi, Su, Tao, Dendy, Meaghan, Lau, Ying-Ka Ingar, Memeo, Lorenzo, Horlings, Hugo M., van de Vijver, Marc J., Isola, Jorma, Hibshoosh, Hanina, Rosen, Neal, Parsons, Ramon, Saal, Lao H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971667/ https://www.ncbi.nlm.nih.gov/pubmed/27484095 http://dx.doi.org/10.1186/s12885-016-2609-2 |
Ejemplares similares
-
PTEN and NEDD4 in Human Breast Carcinoma
por: Chen, Yilun, et al.
Publicado: (2015) -
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
por: Jumppanen, Mervi, et al.
Publicado: (2007) -
Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer
por: Olsson, Eleonor, et al.
Publicado: (2015) -
Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells
por: Pires, Maira M., et al.
Publicado: (2013) -
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
por: Dalal, Hina, et al.
Publicado: (2022)